Abstract
We performed a double-blind, randomized study in investigating the efficacy of mexiletine verus quinidine sulfate in 14 ambulatory patients with an average of at least 30 PVCs per hour for two sequential 24-hour periods of ambulatory monitoring. The double-blind dose of drug was individually titrated for each patient according to efficacy. The mean daily dose of mexiletine was 600 mg in one patient and 900 mg in 5 patients. The mean daily dose of quinidine was 800 mg in 5 patients, 1200 mg in one patient, and 1600 mg in two patients. Adverse effects occurred in three of 8 patients (38%) on quinidine and in 4 of 6 patients (67%) on mexiletine. Two of 8 patients (25%) on quinidine and 4 of 6 patients (67%) on mexiletine had to discontinue the drug because of adverse effects. An average reduction in PVCs of at least 70% during the last two 24-hour recordings on double-blind drug compared with the control period recordings occurred in 4 of 6 patients (67%) on quinidine and in 3 of 6 patients (50%) on mexiletine. Four of 8 patients (50%) on quinidine and one of 6 patients (17%) on mexiletine were able to tolerate the drug and have at least 70% reduction of PVCs.
| Original language | English |
|---|---|
| Pages (from-to) | 1070-1074 |
| Number of pages | 5 |
| Journal | Current Therapeutic Research - Clinical and Experimental |
| Volume | 33 |
| Issue number | 6 II |
| State | Published - 1983 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
Effect of oral mexiletine versus quinidine on premature ventricular complexes. / Esterbrooks, Dennis J.; Mohiuddin, Syed M.; Aronow, W. S.
In: Current Therapeutic Research - Clinical and Experimental, Vol. 33, No. 6 II, 1983, p. 1070-1074.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of oral mexiletine versus quinidine on premature ventricular complexes
AU - Esterbrooks, Dennis J.
AU - Mohiuddin, Syed M.
AU - Aronow, W. S.
PY - 1983
Y1 - 1983
N2 - We performed a double-blind, randomized study in investigating the efficacy of mexiletine verus quinidine sulfate in 14 ambulatory patients with an average of at least 30 PVCs per hour for two sequential 24-hour periods of ambulatory monitoring. The double-blind dose of drug was individually titrated for each patient according to efficacy. The mean daily dose of mexiletine was 600 mg in one patient and 900 mg in 5 patients. The mean daily dose of quinidine was 800 mg in 5 patients, 1200 mg in one patient, and 1600 mg in two patients. Adverse effects occurred in three of 8 patients (38%) on quinidine and in 4 of 6 patients (67%) on mexiletine. Two of 8 patients (25%) on quinidine and 4 of 6 patients (67%) on mexiletine had to discontinue the drug because of adverse effects. An average reduction in PVCs of at least 70% during the last two 24-hour recordings on double-blind drug compared with the control period recordings occurred in 4 of 6 patients (67%) on quinidine and in 3 of 6 patients (50%) on mexiletine. Four of 8 patients (50%) on quinidine and one of 6 patients (17%) on mexiletine were able to tolerate the drug and have at least 70% reduction of PVCs.
AB - We performed a double-blind, randomized study in investigating the efficacy of mexiletine verus quinidine sulfate in 14 ambulatory patients with an average of at least 30 PVCs per hour for two sequential 24-hour periods of ambulatory monitoring. The double-blind dose of drug was individually titrated for each patient according to efficacy. The mean daily dose of mexiletine was 600 mg in one patient and 900 mg in 5 patients. The mean daily dose of quinidine was 800 mg in 5 patients, 1200 mg in one patient, and 1600 mg in two patients. Adverse effects occurred in three of 8 patients (38%) on quinidine and in 4 of 6 patients (67%) on mexiletine. Two of 8 patients (25%) on quinidine and 4 of 6 patients (67%) on mexiletine had to discontinue the drug because of adverse effects. An average reduction in PVCs of at least 70% during the last two 24-hour recordings on double-blind drug compared with the control period recordings occurred in 4 of 6 patients (67%) on quinidine and in 3 of 6 patients (50%) on mexiletine. Four of 8 patients (50%) on quinidine and one of 6 patients (17%) on mexiletine were able to tolerate the drug and have at least 70% reduction of PVCs.
UR - http://www.scopus.com/inward/record.url?scp=0020620716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020620716&partnerID=8YFLogxK
M3 - Article
VL - 33
SP - 1070
EP - 1074
JO - Current Therapeutic Research
JF - Current Therapeutic Research
SN - 0011-393X
IS - 6 II
ER -